Medicenna Therapeutics Corp. Shareholders Approve Reverse Stock Split
Medicenna Therapeutics Corp. shareholders approved a reverse stock consolidation, with a ratio between 1-for-2 and 1-for-20, at the Board's discretion. This move is intended to potentially support a listing on a major U.S. exchange. Directors were also elected, and MNP LLP was re-appointed as the auditor.